Full Press Release Details
Catalyst Pharmaceuticals Announces FIRDAPSE New Drug Application Submitted in
Japan by Partner DyDo Pharma
CORAL GABLES, Fla., Dec 18, 2023 Catalyst Pharmaceuticals,
Inc. ( Catalyst ) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases,
today announced that its collaboration partner, DyDo Pharma, Inc. ( DyDo ), reported that it has submitted a New Drug Application ( NDA ) to Japan s Pharmaceuticals and Medical Devices Agency ( PMDA )
seeking marketing approval for FIRDAPSE (amifampridine) Tablets 10 mg (generic name: amifampridine phosphate), for the treatment of Lambert Eaton myasthenic syndrome ( LEMS )
in Japan. The submission is based on preliminary favorable analysis results of interim data after six months into the safety phase of the registration study to evaluate the efficacy and safety of FIRDAPSE for the treatment of LEMS. The review period
is expected to be approximately a minimum of nine months from the submission date.
The NDA submission to the PMDA by our partner DyDo represents a
pivotal milestone in our mission to broaden FIRDAPSE s access as a treatment for LEMS patients in Japan, stated Patrick J. McEnany, Catalyst s Chairman and CEO. Given the absence of therapies available in Japan for this rare
neuromuscular disorder, we believe that if approved, FIRDAPSE holds the potential to be a novel treatment option for Japanese individuals grappling with this condition. As we continue to collaborate with our partner during the review process, the
submission also triggers an expansion of our territorial rights for the product and a milestone payment to Catalyst. We look forward to initiating our plans to expand the reach for FIRDAPSE into other global regions seeking a novel therapy for the
In June 2021, Catalyst entered into a license agreement with DyDo for the development and commercialization of FIRDAPSE in
Japan. Under the terms of the agreement, Catalyst is eligible to receive a regulatory milestone payment from DyDo upon submission of the NDA to the PMDA. Under the Company s license agreement with SERB S.A., upon acceptance of the NDA
submission to the PMDA in Japan, Catalyst s territorial rights to develop and market the product will automatically extend to other key markets in Asia, Central, and South America. The Company is currently initiating plans to seek opportunities
to expand the product s global footprint through strategic partnerships, with a current focus on the Asia Pacific and Latin American regions.
About FIRDAPSE (amifampridine) Tablets 10 mg
FIRDAPSE (amifampridine) Tablets 10 mg is an oral, nonspecific, voltage-dependent, potassium
(K+) channel blocker that causes depolarization of the presynaptic membrane and slows or inhibits repolarization. This action results in the opening of slow voltage-dependent calcium (Ca2+) channels, allowing for a subsequent influx of Ca2+. In
turn, it induces the exocytosis of synaptic vesicles containing Acetylcholine (ACh) to release more ACh into the synaptic cleft, enhancing neuromuscular transmission and providing for improved muscle function. Amifampridine phosphate was granted
orphan drug designation by the Ministry of Health, Labour, and Welfare in Japan, and FIRDAPSE has previously been approved for use in the United States for adults and for children ages six to seventeen and in Europe and Canada
for the treatment of adults with LEMS.
DyDo Pharma is the rare disease pharmaceutical wholly owned subsidiary of DyDo Group Holdings. DyDo Group Holdings, Inc. operates through the following
segments: Domestic Beverage Business, International Beverage Business, Pharmaceutical-related Business, Food Business, and Other Businesses. The Domestic Beverage Business accounts for more than 70% of total sales, and beverages are sold through
vending machines that are widely prevalent in Japan. The company was founded on January 27, 1975, and is headquartered in Osaka, Japan.
About Catalyst Pharmaceuticals
patient focus, Catalyst is committed to developing and commercializing innovative first-in-class medicines that address rare neurological and epileptic diseases.
Catalyst s flagship U.S. commercial product is FIRDAPSE (amifampridine) Tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome ( LEMS )
for adults and for children ages six to seventeen. In January 2023, Catalyst acquired the U.S. commercial rights to FYCOMPA (perampanel) CIII, a prescription medicine
approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for
people with epilepsy aged 12 and older. Further, Canada s national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Finally,
on July 18, 2023, Catalyst acquired an exclusive license for North America for AGAMREE (vamorolone) oral suspension 40 mg/mL, a novel corticosteroid treatment for Duchenne
Muscular Dystrophy. AGAMREE previously received FDA Orphan Drug and Fast Track designations and was recently approved for commercialization in the U.S. on October 26,
For more information about Catalyst Pharmaceuticals, Inc., visit the Company s website at www.catalystpharma.com. For Full Prescribing
and Safety Information for FIRDAPSE , visit www.firdapse.com. For Full Prescribing Information, including Boxed WARNING for
FYCOMPA , please visit www.fycompa.com. For Full Prescribing Information for AGAMREE , please
visit www.agamree.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause
Catalyst s actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether DyDo Pharma s clinical trial in Japan will be successful, (ii) whether FIRDAPSE will ever be approved for commercialization in Japan, and (iii) those factors described in Catalyst s Annual Report on Form 10-K for
fiscal year 2022 and its other filings with the U.S. Securities and Exchange Commission ( SEC ), could adversely affect Catalyst. Copies of Catalyst s filings with the SEC are available from the SEC, may be
found on Catalyst s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Mary Coleman, Catalyst Pharmaceuticals
David Schull, Russo Partners